Nyaku, M.; Yoon, L.S.; Ricci, D.; Rubens, L.; Sheridan, P.; Iyer, M.; Zhen, T.; Harvey, R.A.; Madsen, A.
Effectiveness of Heterologous and Homologous Ad26.COV2.S Vaccine Boosting in Preventing COVID-19-Related Outcomes Among Individuals with a Completed Primary Vaccination Series in the United States. Vaccines 2025, 13, 166.
https://doi.org/10.3390/vaccines13020166
AMA Style
Nyaku M, Yoon LS, Ricci D, Rubens L, Sheridan P, Iyer M, Zhen T, Harvey RA, Madsen A.
Effectiveness of Heterologous and Homologous Ad26.COV2.S Vaccine Boosting in Preventing COVID-19-Related Outcomes Among Individuals with a Completed Primary Vaccination Series in the United States. Vaccines. 2025; 13(2):166.
https://doi.org/10.3390/vaccines13020166
Chicago/Turabian Style
Nyaku, Mawuli, Lara S. Yoon, Deborah Ricci, Lexie Rubens, Paige Sheridan, Monica Iyer, Thomas Zhen, Raymond A. Harvey, and Ann Madsen.
2025. "Effectiveness of Heterologous and Homologous Ad26.COV2.S Vaccine Boosting in Preventing COVID-19-Related Outcomes Among Individuals with a Completed Primary Vaccination Series in the United States" Vaccines 13, no. 2: 166.
https://doi.org/10.3390/vaccines13020166
APA Style
Nyaku, M., Yoon, L. S., Ricci, D., Rubens, L., Sheridan, P., Iyer, M., Zhen, T., Harvey, R. A., & Madsen, A.
(2025). Effectiveness of Heterologous and Homologous Ad26.COV2.S Vaccine Boosting in Preventing COVID-19-Related Outcomes Among Individuals with a Completed Primary Vaccination Series in the United States. Vaccines, 13(2), 166.
https://doi.org/10.3390/vaccines13020166
